Skip to main content
SpringerLink
Log in

Ionic titanocene complexes: a new type of antitumor agent

  • Original Articles
  • Titanocene, Antitumor Agent, Ehrlich Ascites Tumor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Five ionic cyclopentadienyltitanium(IV) derivatives were investigated for their activity against fluid Ehrlich ascites tumor. Four compounds were built up by the intact bis(cyclopentadienyl)titanium(IV) (“titanocene”) unit, forming the cationic moiety together with two covalently bound ligands, with certain anions being bonded via electrostatic forces: the acetonitrile complex [(C5H5)2TiCl(NCCH3)]+[FeCl4]- (I), the 2,2′-bipyridyl derivative [(C5H5)2Ti(bipy)]2+[CF3SO3]2 (II), the o-phenanthroline complex [(C5H5)2Ti(phen)]2+[CF3SO3]2 (III), and the N-methyl-o-aminothiophenolate derivative {(C5H5)2Ti[o-S(NHCH3)C6H4]}+I- (IV). Another ionic cyclopentadienyltitanium derivative investigated was the five-coordinate bis(dithiolene) chelate [(C5H5)Ti(1,2,4-S2C6H3CH3)2]-[N(C2H5)4]+ (V), the cyclopentadienyltitanium moiety representing the anionic part of the complex salt. All complexes were ionic, salt-like compounds, distinguished by good water solubility. Whereas complexes I, III, and V, given at optimal dose levels, effected maximal cure rates of only 70%–80%, all animals were cured after receiving complexes II and IV at dose ranges of 200–220 and 240–300 mg/kg, respectively. The antitumor activity of complex I was confirmed against solid experimental tumor systems B16 melanoma, colon 38 carcinoma, and Lewis lung carcinosarcoma. Because of their improved solubility in water and pronounced antitumor activity (especially that of II and IV against fluid Ehrlich ascites tumor), ionic cyclopentadienyl titanium complexes are considered to be an interesting new type of antitumor agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adamson RH, Canellos GP, Sieber SM (1975) Studies on the antitumor activity of gallium nitrate (NSC-15 200) and other group IIIa metal salts. Cancer Chemother Rep 59(1): 599–610

    Google Scholar 

  2. Anghileri LJ (1975) The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor. Z Krebsforsch 83: 213–217

    Google Scholar 

  3. Berners-Price SJ, Mirabelli CF, Johnson RK, Mattern MR, McCabe FL, Fancette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST (1986) In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)-ethane]gold(I) chloride. Cancer Res 46: 5486–5493

    Google Scholar 

  4. Clarke MJ (1980) The potential of ruthenium in anticancer pharmaceuticals. In: Martell EA (ed) Inorganic chemistry in biology and medicine. ACS, Washington, DC, pp 157–178

    Google Scholar 

  5. Cleare MJ, Hydes PC, Hepburn DR, Malerbi BW (1980) Antitumor platinum complexes: structure-activity relationships. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin-current status and new developments. Academic Press, New York, pp 149–170

    Google Scholar 

  6. Crowe AJ, Smith PJ, Atassi G (1980) Investigations into the antitumour activity of organotin compounds: I. Diorganotin dihalide and di-pseudohalide complexes. Chem Biol Interact 32: 171–178

    Google Scholar 

  7. Elo HO, Lumme PO (1985) Antitumor activity of trans-bis(salicylaldoximato)copper(II): a novel antiproliferative metal complex. Cancer Treat Rep 69: 1021–1022

    Google Scholar 

  8. Keller HJ, Keppler B, Schmähl D (1982) Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanediazato)titanium(IV) compounds against Walker 256 carcinosarcoma. Arzneim Forsch/Drug Res 32: 806–807

    Google Scholar 

  9. Keppler BK, Schmähl D (1986) Preclinical evaluation of dichloro-bis(1-phenylbutane-1,3-dionato)titanium(IV)and budotitane. Arzneim Forsch/Drug Res 36: 1822–1828

    Google Scholar 

  10. Köpf H, Köpf-Maier P (1979) Titanocen-dichlorid — das erste Metallocen mit cancerostatischer Wirksamkeit. Angew Chem 91: 509; Angew Chem Int Ed Engl 18: 477–478

    Google Scholar 

  11. Köpf H, Klapötke T (1986) 27-1 (IV)- und-zirconium(IV)-Komplexe mit einem oder zwei Toluol-3,4-dithiolat-Liganden. J Organomet Chem 307: 319–325

    Google Scholar 

  12. Köpf H, Klapötke T, Köpf-Maier P (1986) Titanocene mercaptoanilinium derivatives as new antitumor agents. Proceedings of the 192nd National Meeting of the American Chemical Society, Anaheim, Sept 7–12 (Inorg 0132)

  13. Köpf-Maier P (1985) Tumor inhibition by ferricenium complexes: systemic effect in vivo and cell growth inhibition in vitro. Z naturforsch 40c: 843–846

    Google Scholar 

  14. Köpf-Maier P, Köpf H (1979) Vanadocen-dichlorid — ein weiteres Antitumor-Agens aus der Metallocenreihe. Z Naturforsch 34b: 805–807

    Google Scholar 

  15. Köpf-Maier P, Köpf H (1986) Medical use of cytostatic platinum compounds. In: Gmelin handbook of inorganic chemistry, 8th edn. Springer-Verlag, Berlin, pp 318–338

    Google Scholar 

  16. Köpf-Maier P, Köpf H (1987) Non-platinum-group metal antitumor agents: history, current status, and perspectives. Chem Rev 87: 1137–1152

    Google Scholar 

  17. Köpf-Maier P, Hesse B, Voigtländer R, Köpf H (1980) Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F,Cl,Br,I,NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects. J Cancer Res Clin Oncol 97: 31–39

    Google Scholar 

  18. Köpf-Maier P, Köpf H, Neuse EW (1984) Ferricenium complexes — a new type of water-soluble antitumor agent. J Cancer Res Clin Oncol 108: 336–340

    Google Scholar 

  19. Köpf-Maier P, Grabowski S, Liegener J, Köpf H (1985) New antitumor titanocene derivatives containing hydrophilic ligands. Inorg Chim Acta 108: 99–103

    Google Scholar 

  20. Kumano N, Nakai Y, Ishikawa T, Koinumari S, Suzuki S, Konno K (1978) Effect of carboxyethylgermanium sesquioxide on the methylcholanthrene-induced tumorigenesis in mice. Sci Rep Res Inst Tohoku Univ [Med] 25: 89–95

    Google Scholar 

  21. Leh FKV, Wolf W (1976) Platinum complexes: a new class of antineoplastic agents. J Pharm Sci 65: 315–328

    Google Scholar 

  22. Meirim MG, Neuse EW (1984) A chlorotitanocene tetrachloroferrate complex stabilized by acetonitrile coordination. Trans Met Chem 9: 337–338

    Google Scholar 

  23. Mulinos MG, Amin P (1980) Toxicology and phase I study of a new anticancer agent, spirogermanium HCI. Fed Am Soc Exp Biol 39: 747

    Google Scholar 

  24. Rosenberg B (1973) Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 60: 399–406

    Google Scholar 

  25. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303–2316

    Google Scholar 

  26. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222: 385–386

    Google Scholar 

  27. Sadler PJ, Nasr M, Narayanan VL (1984) The design of metal complexes as anticancer drugs. Dev Oncol 17: 290–304

    Google Scholar 

  28. Shaw CF III, Beery A, Stocco GC (1986) Anti-tumor activity of two binuclear gold(I) complexes with bridging dithiolate ligands. Inorg Chim Acta 123: 213–216

    Google Scholar 

  29. Thewalt U, Berhalter K (1986) Kattonische Komplexe mit der (η5-C5H5)2TiIV-Baugruppe: Darstellung und Struktur von [η5-C5H5)2Ti(bipy)]2+(CF3SO3 -)2 und [η5-C5H5)2Ti(phen)]2+(CF3SO3 -)2. J Organomet Chem 302: 193–200

    Google Scholar 

  30. Thewalt U, Berhalter K, Neuse EW (1985) The crystal and molecular structure of acetonitrilechlorodicyclopentadienyltitanium tetrachloroferrate(III). Some Mössbauer and X-ray photoelectron spectroscopic data. Trans Met Chem 10: 393–395

    Google Scholar 

  31. Weiss GR, Kisner DL, Kuhn JG, Melink TJ, Meyers JW, Von Hoff DD (1984) New anticancer agents. In: Pinedo HM, Chabner BA (eds) Cancer chemotherapy annual 6. Elsevier, Amsterdam pp 133–162

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Anatomie, Freie Universität Berlin, Königin-Luise-Straße 15, D-1000, Berlin 33

    P. Köpf-Maier

  2. Department of Chemistry, University of the Witwatersrand, 2001, Johannesburg, South Africa

    E. Neuse

  3. Institut für Anorganische und Analytische Chemie, Technische Universität Berlin, D-1000, Berlin 12

    T. Klapötke & H. Köpf

Authors
  1. P. Köpf-Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Neuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Klapötke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Köpf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köpf-Maier, P., Neuse, E., Klapötke, T. et al. Ionic titanocene complexes: a new type of antitumor agent. Cancer Chemother. Pharmacol. 24, 23–27 (1989). https://doi.org/10.1007/BF00254100

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254100

Keywords

Search

Navigation